Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 7/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | NEK2 | P51955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100554 | 0.89 | FYN (0.38) | GRIN2BKCNN4GRIN1NEK2 | |
| SCHEMBL10100556 | 0.89 | NEK2 (0.35) | GRIN2BKCNN4GRIN1NEK2 | |
| SCHEMBL10100575 | 0.87 | KCNN4 (0.33) | GRIN2BKCNN4GRIN1TDP1NEK2 | |
| SCHEMBL10100495 | 0.87 | FYN (0.35) | KCNN4 | |
| SCHEMBL10100655 | 0.87 | NEK2 (0.37) | GRIN2BKCNN4NEK2 | |
| SCHEMBL10100492 | 0.86 | EPHX2 (0.42) | KCNN4 | |
| SCHEMBL10100496 | 0.86 | ACHE (0.38) | KCNN4 | |
| SCHEMBL10100506 | 0.85 | FYN (0.44) | GRIN2BKCNN4 | |
| SCHEMBL10100477 | 0.84 | KCNN4 (0.32) | KCNN4 | |
| SCHEMBL10100559 | 0.84 | KIT (0.37) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | GRIN2B 3446/4885KCNN4 4066/4885GRIN1 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.